SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ranjana H. Advani, Stephen M. Ansell, Mary J. Lechowicz, Anne W. Beaven, Fausto Loberiza, Kenneth R. Carson, Andrew M. Evens, Francine Foss, Steven Horwitz, Barbara Pro, Lauren C. Pinter-Brown, Sonali M. Smith, Andrei R. Shustov, Kerry J. Savage, Julie M. Vose, A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial, British Journal of Haematology, 2016, 172, 4
  2. 2
    Bo Jia, Shaoxuan Hu, Jianliang Yang, Shengyu Zhou, Peng Liu, Yan Qin, Lin Gui, Sheng Yang, Hua Lin, Changgong Zhang, Puyuan Xing, Lin Wang, Mei Dong, Liqiang Zhou, Yan Sun, Xiaohui He, Yuankai Shi, Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas, Hematology, 2016, 1

    CrossRef

  3. 3
    Jing-jing Wang, Mei Dong, Xiao-hui He, Ye-xiong Li, Wei-hu Wang, Peng Liu, Jian-liang Yang, Lin Gui, Chang-gong Zhang, Sheng Yang, Sheng-yu Zhou, Yuan-kai Shi, GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Medicine, 2016, 95, 6, e2787

    CrossRef

  4. 4
    Stephen Ansell, How to select the frontline treatment for a patient with peripheral T-cell lymphoma, Leukemia & Lymphoma, 2016, 57, 4, 783

    CrossRef

  5. 5
    F. d'Amore, P. Gaulard, L. Trümper, P. Corradini, W.-S. Kim, L. Specht, M. Bjerregaard Pedersen, M. Ladetto, Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, 2015, 26, suppl 5, v108

    CrossRef

  6. 6
    Byeong-Bae Park, Won Seog Kim, Cheolwon Suh, Dong-Yeop Shin, Jeong-A Kim, Hoon-Gu Kim, Won Sik Lee, Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial, Annals of Hematology, 2015, 94, 11, 1845

    CrossRef

  7. 7
    Eve Gallop-Evans, The role of alisertib in treatment of peripheral T-cell lymphomas, Future Oncology, 2015, 11, 18, 2515

    CrossRef

  8. You have free access to this content8
    Greg Hapgood, Kerry J. Savage, X. Challenges and future directions in peripheral T-cell lymphoma, Hematological Oncology, 2015, 33,
  9. 9
    J. W. Hsu, N. H. Dang, ALK1 as a Novel Therapeutic Target for CD30+ T-Anaplastic Large Cell Lymphoma, JNCI Journal of the National Cancer Institute, 2014, 106, 2, djt454

    CrossRef

  10. 10
    Kristen Ganjoo, Fangxin Hong, Sandra J. Horning, Randy D. Gascoyne, Yasodha Natkunam, Lode J. Swinnen, Thomas M. Habermann, Brad S. Kahl, Ranjana H. Advani, Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404), Leukemia & Lymphoma, 2014, 55, 4, 768

    CrossRef

  11. 11
    Nishitha M. Reddy, Andrew M. Evens, Chemotherapeutic Advancements in Peripheral T-Cell Lymphoma, Seminars in Hematology, 2014, 51, 1, 17

    CrossRef

  12. 12
    Zhiyuan Zhou, Xiang Li, Changying Chen, Xin Li, Lei Zhang, Ling Li, Xinhua Wang, Wang Ma, Xiaorui Fu, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Zhaoming Li, Jiaqin Yan, Yu Chang, Lisha Lu, Beibei Qin, Xiaoli Li, Jianguo Wen, Mingzhi Zhang, Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients, Annals of Hematology, 2014, 93, 11, 1889

    CrossRef

  13. 13
    Andrew M. Intlekofer, Anas Younes, From empiric to mechanism-based therapy for peripheral T cell lymphoma, International Journal of Hematology, 2014, 99, 3, 249

    CrossRef

  14. 14
    A. J. Moskowitz, M. A. Lunning, S. M. Horwitz, How I treat the peripheral T-cell lymphomas, Blood, 2014, 123, 17, 2636

    CrossRef

  15. 15
    S. M. Horwitz, R. H. Advani, N. L. Bartlett, E. D. Jacobsen, J. P. Sharman, O. A. O'Connor, T. Siddiqi, D. A. Kennedy, Y. Oki, Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin, Blood, 2014, 123, 20, 3095

    CrossRef

  16. 16
    Pier Paolo Piccaluga, Anna Gazzola, Claudia Mannu, Stefano A Pileri, Pier Luigi Zinzani, Past, present and future treatment strategies in peripheral T-cell lymphomas, International Journal of Hematologic Oncology, 2014, 3, 4, 299

    CrossRef

  17. 17
    Maria Gkotzamanidou, Christos A. Papadimitriou, Peripheral T-cell lymphoma: The role of hematopoietic stem cell transplantation, Critical Reviews in Oncology/Hematology, 2014, 89, 2, 248

    CrossRef

  18. 18
    Kevin R. Kelly, Thomas C. Shea, André Goy, Jesus G. Berdeja, Craig B. Reeder, Kevin T. McDonagh, Xiaofei Zhou, Hadi Danaee, Hua Liu, Jeffrey A. Ecsedy, Huifeng Niu, Ely Benaim, Swaminathan Padmanabhan Iyer, Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia, Investigational New Drugs, 2014, 32, 3, 489

    CrossRef

  19. 19
    F. Ellin, J. Landstrom, M. Jerkeman, T. Relander, Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry, Blood, 2014, 124, 10, 1570

    CrossRef

  20. 20
    P. Corradini, M. Marchetti, G. Barosi, A. Billio, A. Gallamini, S. Pileri, N. Pimpinelli, G. Rossi, P. L. Zinzani, S. Tura, SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias, Annals of Oncology, 2014, 25, 12, 2339

    CrossRef

  21. 21
    Roopesh Kansara, Kerry J. Savage, The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma, Leukemia & Lymphoma, 2014, 55, 4, 727

    CrossRef

  22. 22
    R Briski, A L Feldman, N G Bailey, M S Lim, K Ristow, T M Habermann, W R Macon, D J Inwards, J P Colgan, G S Nowakowski, M S Kaminski, T E Witzig, S M Ansell, R A Wilcox, The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas, Blood Cancer Journal, 2014, 4, 5, e214

    CrossRef

  23. 23
    Koppany Visnyei, Michael L. Grossbard, Ilan Shapira, Hepatosplenic γδ T-cell Lymphoma: An Overview, Clinical Lymphoma Myeloma and Leukemia, 2013, 13, 4, 360

    CrossRef

  24. 24
    Matthew A. Lunning, Steven Horwitz, Treatment of Peripheral T-cell Lymphoma: Are We Data Driven or Driving the Data?, Current Treatment Options in Oncology, 2013, 14, 2, 212

    CrossRef

  25. 25
    Jasmine Zain, Sandra H. Thomas, Hematopoietic Cell Transplantation for Non'Hodgkin Lymphoma (T Cell),